Drug Resistance Updates
Volume 1, Issue 6 , Pages 389-396 , 1998

P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates

  • Christopher V. Plowe

      Affiliations

    • Molecular Parasitology and Malaria Field Studies Unit, Center for Vaccine Development/Division of Geographic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
    • Corresponding Author InformationCorrespondence to: Christopher V. Plowe MD, MPH, Molecular Parasitology and Malaria Field Studies Unit, Center for Vaccine Development/Division of Geographic Medicine, University of Maryland School of Medicine, 685 West Baltimore Street, HSF 480, Baltimore, Maryland 21201 USA, Tel: 410-706-5328; Fax: 410-706-6205
    • ,
  • James G. Kublin

      Affiliations

    • Molecular Parasitology and Malaria Field Studies Unit, Center for Vaccine Development/Division of Geographic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
    • ,
  • Ogobara K. Doumbo

      Affiliations

    • Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto-stomatology, University of Mali, Bamako, Mali

Received 16 July 1998 ,Revised 19 October 1998 ,Accepted 20 October 1998.

References 

  1. Peters W. Chemotherapy and Drug Resistance in Malaria. London: Academic Press; 1987;
  2. Jones AS. Mass treatment with pyrimethamine. A study of resistance and cross resistance resulting from a field trial in the hyperendemic malarious area of Makueni, Kenya, September 1952–September 1953. Trans R Soc Trop Med Hyg. 1958;52:547
  3. World Health Organization Technical Report Series: Malaria Chemotherapy. Geneva: World Health Organization; 1990;
  4. Radloff PD, Philipps J, Nkeyi M, et al. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996;347:1511–1514
  5. Amukoye E, Winstanley PA, Watkins WM, et al. Chlorproguanildapsone: an effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother. 1997;41:2261–2264
  6. Rieckmann KH, Yeo AE, Edstein MD. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans R Soc Trop Med Hyg. 1996;90:568–571
  7. Plowe CV, Djimde A, Bouare M, et al. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565–568
  8. Nguyen-Dinh P, Payne D. Pyrimethamine sensitivity in Plasmodium falciparum: determination in vitro by a modified 48-hour test. Bull World Health Organ. 1980;58:909–912
  9. (in press) Triglia T, Cowman AF. The mechanism of resistance to sulfa drugs in Plasmodium falciparum. Drug Resistance Updates. 1998;
  10. Sirawaraporn W. Dihydrofolate reductase and antifolate resistance in malaria. Drug Resistance Updates. 1998;1:397–406
  11. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. In: Proc Natl Acad Sci USA. 85:1988;p. 9114–9118
  12. Cowman AF, Morry MJ, Biggs BA, et al. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. In: Proc Natl Acad Sci USA. 85:1988;p. 9109–9113
  13. Snewin VA, England SM, Sims PF, Hyde JE. Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene. 1989;76:41–52
  14. Zolg JW, Plitt JR, Chen GX, Palmer S. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1989;36:253–262
  15. Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. In: Proc Natl Acad Sci USA. 87:1990;p. 3018–3022
  16. Foote SJ, Galatis D, Cowman AF. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. In: Proc Natl Acad Sci USA. 87:1990;p. 3014–3017
  17. Brooks DR, Wang P, Read M, et al. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 1994;224:397–405
  18. Triglia T, Cowman AF. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. In: Proc Natl Acad Sci USA. 91:1994;p. 7149–7153
  19. Wang P, Read M, Sims PF, Hyde JE. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Molec Microbiol. 1997;23:979–986
  20. Triglia T, Menting JGT, Wilson C, et al. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. In: Proc Natl Acad Sci USA. 94:1997;p. 13944–13949
  21. Wu Y, Kirkman LA, Wellems TE. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. In: Proc Natl Acad Sci USA. 93:1996;p. 1130–1134
  22. Triglia T, Wang P, Sims PG, et al. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihyropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 1998;17:3807–3815
  23. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997;176:1590–1596
  24. Wang P, Lee C-S, Bayoumi R, et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol. 1997;89:161–177
  25. Gyang FN, Peterson DS, Wellems TE. Plasmodium falciparum: rapid detection of dihydrofolate reductase mutations that confer resistance to cycloguanil and pyrimethamine. Exp Parasitol. 1992;74:470–472
  26. Duraisingh MT, Curtis J, Warhurst DC, et al. Plasmodium falciparum — detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol. 1998;89:1–8
  27. Peterson DS, Di Santi SM, Povoa M, et al. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am J Trop Med Hyg. 1991;45:492–497
  28. Wang P, Brooks DR, Sims PF, Hyde JE. A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum. Mol Biochem Parasitol. 1995;71:115–125
  29. Shaio MF, Wang P, Lee CS, et al. Development and comparison of quantitative assays for the dihydropteroate synthetase codon 540 mutation associated with sulfadoxine resistance in Plasmodium falciparum. Parasitology. 1998;116:203–210
  30. Plowe CV, Djimde A, Wellems TE, et al. Community pyrimethamine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: A model for deterring resistance. Am J Trop Med Hyg. 1996;55:467–471
  31. Curtis J, Duraisingh MT, Trigg JK, et al. Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania. Trans R Soc Trop Med Hyg. 1996;90:678–680
  32. Edoh D, Mshinda H, Jenkins J, Burger M. Pyrimethamine-resistant Plasmodium falciparum parasites among Tanzanian children: A facility-based study using the polymerase chain reaction. Am J Trop Med Hyg. 1997;57:342–347
  33. Nguyen-Dinh P, Spencer HC, Chemangey-Masaba S, Churchill FC. Susceptibility of Plasmodium falciparum to pyrimethamine and sulfadoxine/pyrimethamine in Kisumu, Kenya. Lancet. 1982;1:823–825
  34. Schapira A, Bygbjerg IC, Jepsen S, et al. The susceptibility of Plasmodium falciparum to sulfadoxine and pyrimethamine: correlation of in vivo and in vitro results. Am J Trop Med Hyg. 1986;35:239–245
  35. Watkins WM, Mberu EK, Winstanley PA, Plowe CV. The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmadocynamic and pharmacokinetic analyses. parasitol Today. 1997;13:459–464
  36. Chulay JD, Watkins WM, Sixsmith DG. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1984;33:325–330
  37. Krungkrai J, Webster HK, Yuthavong Y. De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum. Mol Biochem Parasitol. 1989;32:25–37
  38. van Hensbroek MB, Morris-Jones S, Meisner S, et al. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg. 1995;89:672–676
  39. Suppl Marsh K. Malaria- a neglected disease?. Parasitology. 1992;104:S53–S69
  40. Baird JK, Basri H, Jones TR, et al. Resistance to antimalarials by Plasmodium falciparum in Arso PIR, Irian Jaya, Indonesia. Am J Trop Med Hyg. 1991;44:640–644
  41. Watkins WM, Mberu EK, Nevill CG, et al. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg. 1990;84:492–495
  42. In: Advances in Malaria Chemotherapy. 711:Geneva: World Health Organization; 1984;p. 29
  43. Plowe CV, Djimde A, Wellems TE, et al. Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am J Trop Med Hyg. 1996;55:467–471
  44. (in press) Diourte Y, Djimde A, Doumbo OK, et al. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg. 1998;
  45. Jelinek T, Ronn AM, Curtis J, et al. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance. Trop Med Int Health. 1997;2:1075–1079
  46. Basco LK, Eldin de Pecoulas P, Wilson CM, et al. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1995;69:135–138
  47. Reeder JC, Rieckmann KH, Genton B, et al. Point mutations in the dihydrofolate reductase and dihydropteroate synthatase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg. 1996;55:209–213
  48. Basco LK, Ringwald P. Molecular epidemiology of malaria in Yaounde, Cameroon II. Baseline frequency of point mutations in the dihydropteroate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg. 1998;58:374–377
  49. Basco LK, Ringwald P. Molecular epidemiology of malaria in Yaounde, Cameroon I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg. 1998;58:369–373
  50. Zindrou S, Dung NP, Sy ND, et al. Plasmodium falciparum: Mutation pattern in the dihydrofolate reductase-thymidylate synthase genes of Vietnamese isolates, a novel mutation, and coexistence of two clones in a Thai patient. Exp Parasitol. 1996;84:56–64
  51. Kublin JG, Witzig RS, Shankar AH, et al. Molecular assays for surveillance of antifolate-resistant malaria. Lancet. 1998;351:1629–1630
  52. Cortese JF, Plowe CV. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutants expressed in yeast. Mol Biochem Parasitol. 1998;94:205–214
  53. Clyde DF, Shute GT. Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg. 1957;51:505–513
  54. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg. 1993;87:75–78
  55. Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg. 1994;51:515–522
  56. Curtis J, Duraisingh MT, Warhurst DC. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanildapsone treatment. J Infect Dis. 1998;177:1429–1433
  57. Sirawaraporn W, Sathitkul T, Sirawaraporn R, et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. In: Proc Natl Acad Sci USA. 94:1997;p. 1124–1129
  58. Paul RE, Packer MJ, Walmsley M, et al. Mating patterns in malaria parasite populations of Papua New Guinea. Science. 1995;269:1709–1711
  59. Mackinnon MJ. Survival probability of drug resistant mutants in malaria parasites. In: Proceedings of the Royal Society of London — Series B: Biological Sciences. 1997;p. 53–59
  60. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. N Engl J Med. 1998;338:1641–1649

PII: S1368-7646(98)80014-9

Drug Resistance Updates
Volume 1, Issue 6 , Pages 389-396 , 1998

Article Tools